GSK_Annual_Report_2021

Notes to the Consolidated Financial Statements for the year ended March 31, 2021 (contd.) Annual Report 2020-21 219 2 The following transactions were carried out with the related parties in the ordinary course of business: (i) Dividend paid to parties referred to in item 1(i) above: ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 Glaxo Group Limited, U.K. 219,49.38 121,94.10 GlaxoSmithKline Pte Limited, Singapore 171,37.45 95,20.80 Eskaylab Limited, U.K. 42,33.60 23,52.00 Burroughs Wellcome International Limited, U.K. 24,19.20 13,44.00 (ii) Details relating to parties referred to in items 1(i) and 1(ii) above: ( ` in lakhs) Holding company/ultimate holding company 1(i) Other companies in the GSK Group 1(ii) Year ended March 31, 2021 Year ended March 31, 2020 Year ended March 31, 2021 Year ended March 31, 2020 1 Purchase of materials/traded goods - - 629,73.24 634,52.35 2 Sale of materials/sale of products - - 9,95.96 23.92 3 Sale of laptops - - - 28.56 4 Expenses recharged to other companies - 36.05 17,62.76 27,93.64 5 Expenses recharged by other companies 49.56 - 96,35.07 74,67.46 6 Manufacturing charges recovered - - 4,31.95 13,84.54 7 Clinical research and data management recoveries - - 9,36.45 8,98.26 8 Liabilities written back - - 77.24 - 9 Employee benefit liabilities transferred to a related party - - 19.86 13.51 10 Outstanding receivables at the period end - - 17,74.40 7,30.82 11 Outstanding payables at the period end 46.17 - 118,94.44 56,77.24 12 Cross charges recoverable at the period end - - 4.82 1,25.22 (iii) Disclosure in respect of material transactions with parties referred to in item 1 (i) and 1(ii) above: ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 (a) Purchase of materials / traded goods: GlaxoSmithKline Asia Private Limited, India 12,33.36 15,78.80 GlaxoSmithKline Biologicals S.A., Belgium 540,30.11 497,07.76 Stiefel India Private Limited, India 10,51.03 29,26.99 GlaxoSmithKline Export Limited, U.K. 66,58.74 85,60.10 (b) Sale of materials/sale of products: GlaxoSmithKline Trading Services Limited, Ireland 63.17 23.92 GlaxoSmithKline Export Limited, U.K. 9,32.79 -